Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1994 2
1995 8
1996 11
1997 14
1998 9
1999 14
2000 12
2001 17
2002 10
2003 14
2004 19
2005 15
2006 17
2007 16
2008 21
2009 23
2010 24
2011 26
2012 27
2013 31
2014 39
2015 60
2016 81
2017 119
2018 149
2019 175
2020 213
2021 261
2022 229
2023 292
2024 80

Text availability

Article attribute

Article type

Publication date

Search Results

1,782 results

Results by year

Filters applied: . Clear all
Page 1
Breast cancer.
Loibl S, Poortmans P, Morrow M, Denkert C, Curigliano G. Loibl S, et al. Lancet. 2021 May 8;397(10286):1750-1769. doi: 10.1016/S0140-6736(20)32381-3. Epub 2021 Apr 1. Lancet. 2021. PMID: 33812473 Review.
ER-positive tumours are treated with 5-10 years of endocrine therapy and chemotherapy, based on an individual risk assessment. For metastatic breast cancer, standard therapy options include targeted approaches such as CDK4 and CDK6 inhibitors, PI3K inhibitors, PARP …
ER-positive tumours are treated with 5-10 years of endocrine therapy and chemotherapy, based on an individual risk assessment. For metastati …
Targeting Cell Cycle in Breast Cancer: CDK4/6 Inhibitors.
Piezzo M, Cocco S, Caputo R, Cianniello D, Gioia GD, Lauro VD, Fusco G, Martinelli C, Nuzzo F, Pensabene M, De Laurentiis M. Piezzo M, et al. Int J Mol Sci. 2020 Sep 4;21(18):6479. doi: 10.3390/ijms21186479. Int J Mol Sci. 2020. PMID: 32899866 Free PMC article. Review.
Up to now, three CDK4/6 inhibitors have been approved by FDA for the treatment of hormone receptor-positive (HR+), HER2-negative metastatic breast cancer. ...This review summarizes the available knowledge regarding CDK4/6 inhibitor, the discovery of new bioma …
Up to now, three CDK4/6 inhibitors have been approved by FDA for the treatment of hormone receptor-positive (HR+), HER2-negative meta …
CDK4/6 inhibitor resistance mechanisms and treatment strategies (Review).
Huang J, Zheng L, Sun Z, Li J. Huang J, et al. Int J Mol Med. 2022 Oct;50(4):128. doi: 10.3892/ijmm.2022.5184. Epub 2022 Aug 31. Int J Mol Med. 2022. PMID: 36043521 Free PMC article. Review.
Among all breast cancer subtypes, the hormone receptor (HR)(+)/human epidermal growth factor receptor 2 (HER2)(-) luminal subtype breast cancer is the most common form of breast cancer. Cyclin-dependent kinase 4 and 6 (CDK4/6) inhibitors, the hotspots …
Among all breast cancer subtypes, the hormone receptor (HR)(+)/human epidermal growth factor receptor 2 (HER2)(-) luminal subtype …
Early Adaptation and Acquired Resistance to CDK4/6 Inhibition in Estrogen Receptor-Positive Breast Cancer.
Herrera-Abreu MT, Palafox M, Asghar U, Rivas MA, Cutts RJ, Garcia-Murillas I, Pearson A, Guzman M, Rodriguez O, Grueso J, Bellet M, Cortés J, Elliott R, Pancholi S, Baselga J, Dowsett M, Martin LA, Turner NC, Serra V. Herrera-Abreu MT, et al. Cancer Res. 2016 Apr 15;76(8):2301-13. doi: 10.1158/0008-5472.CAN-15-0728. Epub 2016 Mar 28. Cancer Res. 2016. PMID: 27020857 Free PMC article.
Small-molecule inhibitors of the CDK4/6 cell-cycle kinases have shown clinical efficacy in estrogen receptor (ER)-positive metastatic breast cancer, although their cytostatic effects are limited by primary and acquired resistance. Here we report that ER-positive …
Small-molecule inhibitors of the CDK4/6 cell-cycle kinases have shown clinical efficacy in estrogen receptor (ER)-positive metastatic …
Molecular mechanisms of resistance to CDK4/6 inhibitors in breast cancer: A review.
Pandey K, An HJ, Kim SK, Lee SA, Kim S, Lim SM, Kim GM, Sohn J, Moon YW. Pandey K, et al. Int J Cancer. 2019 Sep 1;145(5):1179-1188. doi: 10.1002/ijc.32020. Epub 2019 Jan 7. Int J Cancer. 2019. PMID: 30478914 Free PMC article. Review.
Deregulation of the cyclin D-CDK4/6-INK4-RB pathway leading to uncontrolled cell proliferation, is frequently observed in breast cancer. Currently, three selective CDK4/6 inhibitors have been FDA approved: palbociclib, ribociclib and abemaciclib. ...
Deregulation of the cyclin D-CDK4/6-INK4-RB pathway leading to uncontrolled cell proliferation, is frequently observed in breast …
Molecular Residual Disease in Breast Cancer: Detection and Therapeutic Interception.
Medford AJ, Moy B, Spring LM, Hurvitz SA, Turner NC, Bardia A. Medford AJ, et al. Clin Cancer Res. 2023 Nov 14;29(22):4540-4548. doi: 10.1158/1078-0432.CCR-23-0757. Clin Cancer Res. 2023. PMID: 37477704 Review.
Breast cancer remains a leading cause of cancer-related death in women despite screening and therapeutic advances. ...There are currently ongoing trials evaluating the efficacy of therapy escalation in the setting of MRD, and these studies are being conducted in all major …
Breast cancer remains a leading cause of cancer-related death in women despite screening and therapeutic advances. ...There are curre …
CDK4/6 inhibition triggers anti-tumour immunity.
Goel S, DeCristo MJ, Watt AC, BrinJones H, Sceneay J, Li BB, Khan N, Ubellacker JM, Xie S, Metzger-Filho O, Hoog J, Ellis MJ, Ma CX, Ramm S, Krop IE, Winer EP, Roberts TM, Kim HJ, McAllister SS, Zhao JJ. Goel S, et al. Nature. 2017 Aug 24;548(7668):471-475. doi: 10.1038/nature23465. Epub 2017 Aug 16. Nature. 2017. PMID: 28813415 Free PMC article.
Pharmacological inhibitors of CDK4/6 have shown significant activity against several solid tumours. ...We confirm this phenomenon through transcriptomic analysis of serial biopsies from a clinical trial of CDK4/6 inhibitor treatment for breast cancer. The enh …
Pharmacological inhibitors of CDK4/6 have shown significant activity against several solid tumours. ...We confirm this phenomenon thr …
Overexpressed Cyclin D1 and CDK4 proteins are responsible for the resistance to CDK4/6 inhibitor in breast cancer that can be reversed by PI3K/mTOR inhibitors.
Cai Z, Wang J, Li Y, Shi Q, Jin L, Li S, Zhu M, Wang Q, Wong LL, Yang W, Lai H, Gong C, Yao Y, Liu Y, Zhang J, Yao H, Liu Q. Cai Z, et al. Sci China Life Sci. 2023 Jan;66(1):94-109. doi: 10.1007/s11427-021-2140-8. Epub 2022 Aug 11. Sci China Life Sci. 2023. PMID: 35982377
CDK4/6 inhibitors are the standard treatment in advanced HR+/HER2- breast cancer patients. ...In conclusion, our findings suggest that overexpressed Cyclin D1 and CDK4 proteins lead to the resistance to CDK4/6 inhibitor and PI3K/mTOR inhibitors are abl …
CDK4/6 inhibitors are the standard treatment in advanced HR+/HER2- breast cancer patients. ...In conclusion, our findings sugg …
LncRNA EILA promotes CDK4/6 inhibitor resistance in breast cancer by stabilizing cyclin E1 protein.
Cai Z, Shi Q, Li Y, Jin L, Li S, Wong LL, Wang J, Jiang X, Zhu M, Lin J, Wang Q, Yang W, Liu Y, Zhang J, Gong C, Yao H, Yao Y, Liu Q. Cai Z, et al. Sci Adv. 2023 Oct 6;9(40):eadi3821. doi: 10.1126/sciadv.adi3821. Epub 2023 Oct 6. Sci Adv. 2023. PMID: 37801505 Free PMC article.
CDK4/6 inhibitors (CDK4/6i) plus endocrine therapy are now standard first-line therapy for advanced HR(+)/HER2(-) breast cancer, but developing resistance is just a matter of time in these patients. Here, we report that a cyclin E1-interacting lncRNA (EILA) i …
CDK4/6 inhibitors (CDK4/6i) plus endocrine therapy are now standard first-line therapy for advanced HR(+)/HER2(-) breast …
Breast Cancer Mutations HER2V777L and PIK3CAH1047R Activate the p21-CDK4/6-Cyclin D1 Axis to Drive Tumorigenesis and Drug Resistance.
Cheng X, Sun Y, Highkin M, Vemalapally N, Jin X, Zhou B, Prior JL, Tipton AR, Li S, Iliuk A, Achilefu S, Hagemann IS, Edwards JR, Bose R. Cheng X, et al. Cancer Res. 2023 Sep 1;83(17):2839-2857. doi: 10.1158/0008-5472.CAN-22-3558. Cancer Res. 2023. PMID: 37272756 Free PMC article.
Combining neratinib with CDK4/6 inhibitors was another effective strategy for treating HP breast cancers, with neratinib plus palbociclib showing a statistically significant reduction in development of mouse HP tumors as compared to either drug alone. ...SIGNIFICANC …
Combining neratinib with CDK4/6 inhibitors was another effective strategy for treating HP breast cancers, with neratinib plus …
1,782 results